Topline results: TP-03 improves meibomian gland disease measures in patients with Demodex
Click Here to Manage Email Alerts
Tarsus Pharmaceuticals has announced positive topline results from the Ersa phase 2a trial evaluating TP-03 for treatment of meibomian gland disease in patients with Demodex mites, with significant improvements reported in two key measures.
According to a company press release, patients treated with twice-daily TP-03 (lotilaner ophthalmic solution, 0.25%) had an increase of 10.5 in mean meibomian gland secretion score from baseline to day 85, while those treated three times a day had an increase of 11.7, both of which were statistically significant.
Tarsus also reported significant improvement from baseline in the mean number of meibomian glands secreting clear liquid, with an increase of 4.8 and 5.3 in each treatment group, respectively.
In addition, statistically significant results were reported in collarette cure and lid margin erythema cure, findings that were consistent with previous studies. TP-03 also was well-tolerated.
“We are encouraged by these early results, which underscore the potential of TP-03 to address the underlying cause of disease,” Bobak Azamian, MD, PhD, CEO and chairman of Tarsus, said in the release.
Earlier this year, the FDA approved TP-03 as Xdemvy for treatment of Demodex blepharitis. The therapeutic works by selecting inhibiting parasite-specific gamma-aminobutyric acid-gated chloride channels, thereby paralyzing and eradicating the mites, the release stated.
Read more about
Click Here to Manage Email Alerts